leisure time -WSS

leisure time

author：entertainment 2025-10-03 00:22:18 - browse：5683

Photo of an arrangement of aspirin pills — Patrick Sison/AP

Low-dose aspirin led to a reduction in liver fat among patients with metabolic-associated liver disease, a small study out of Boston found.

The clinical trial, led by Tracey Simon of Massachusetts General Hospital and Harvard Medical School, compared two groups of patients with metabolic dysfunction-associated steatotic liver disease, or MASLD. One group was given baby aspirin daily for six months, while the other received a placebo pill. At the end of the study period, the aspirin group had reduced hepatic fat content while the placebo group had higher fat buildup.

MASLD (formerly known as non-alcoholic fatty liver disease) is a growing health threat, with 1 in 3 Americans having a troublesome amount of fat in their liver. The lipid buildup feeds into a toxic cycle of inflammation, tissue damage and, ultimately, irreversible scarring.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Why are elite athletes different? Take a look at their microbes

WSS

CDC concerned about possible undetected monkeypox spread in U.K.

FDA rejects Alnylam's heart disease treatment over insufficient data

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

VC firm General Catalyst wants to buy a health system

Do masks work? RCTs can't tell us

Why are elite athletes different? Take a look at their microbes

focus

leisure time

knowledge

Tori Bowie and the unacceptable rates of Black maternal death

Why drug prescriptions should include diagnoses

Cancer drug shortages should be causing more outrage

With FDA staff opposed to Sarepta therapy, top official intervened

BioMarin wins approval for gene therapy to treat hemophilia A

Weight bias in eating disorder treatment complicated by new weight loss drugs

Medical records are filled with copy

Cloning humans is technically possible. It's curious no one has tried

Dobbs anniversary: the lost opportunity of abortion as health care

New guidelines on severe brain injury complicate already difficult decisions

leisure time

The strategy behind pharma's lawsuits over drug pricing reform

Why we need to separate burnout from moral injury in health care

Ask STAT: What do you want to know about ChatGPT in medicine?

AI can decode, harness the power of the humane immune system

Was Amgen transparent enough on FDA's concern on cancer drug?

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

focus

knowledge

entertainment

hotspot